Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.

The Science of Launching and Achieving Growth in Oncology

9 110 vues

Publié le

We have conducted research to understand how oncology companies are responding to New science, more treatment choices and changing economics. Visit https://accntu.re/2Jn72wq to learn our key takeaways for launching and achieving growth in oncology.

Publié dans : Technologie

Les commentaires sont fermés

  • Soyez le premier à commenter

The Science of Launching and Achieving Growth in Oncology

  1. 1. Patient Inspired. Outcomes Driven. LAUNCHINGAND ACHIEVING GROWTHIN ONCOLOGY
  2. 2. Copyright © 2019 Accenture All rights reserved. New Science Is a new mechanism, modality, indication or health technology identified by the FDA or other regulatory entity as having met an unmet need, exceeding standard of care; often involves a technology companion but can be the technology alone 2
  3. 3. 3 NEWSCIENCEISCHANGINGTHEHEALTHCARE LANDSCAPE Copyright © 2019 Accenture All rights reserved. • 54% of industry sales by 2022 driven by new science • 6-7 x’s higher investment in digital, data and genomics by the industry leaders • Emerging decision makers beyond doctors/HCPs, such as patients, care givers, payers, pharmacies/ dispensers, and advocacy groups • Growing importance of patient experience and outcomes • Shifting from price to value …FUNDAMENTALLY CHANGING THE WAY WE SUCCESSFULLY LAUNCH ONCOLOGY PRODUCTS IN THE FUTURE GROWTH OF NEW SCIENCE… …IN THE EVOLVING ECOSYSTEM
  4. 4. 4 NEWSCIENCEISDRIVINGEXCEPTIONALGROWTH acrossmultipletherapeuticareas,butprimarilyinoncology NEW SCIENCE % OF SALES IN THERAPEUTIC AREAS Source: Accenture analysis, data provided by Evaluate Pharma Copyright © 2019 Accenture All rights reserved.
  5. 5. Copyright © 2019 Accenture All rights reserved. In this increasingly complex health ecosystem, how are leading oncology companies driving growth and changing how they launch their treatments? 5
  6. 6. Copyright © 2019 Accenture All rights reserved. RISE OF NEW SCIENCE INCREASE IN TREATMENT CHOICES CHANGING ECONOMICS 6 3TRENDSINFLUENCINGGROWTHIN ONCOLOGYINTHISNEWENVIRONMENT
  7. 7. COMPETITIONISACCELERATING Copyright © 2019 Accenture All rights reserved. 300+New oncology treatment options by 20231,2 Breast Lung Leukemia Prostate Uterine corpus Colon& rectum Melanoma Liver Non-Hodgkin lymphoma Kidney and renal pelvis Pancreas Urinary bladder Thyroid Oral cavity & pharynx 0 30 60 90 120 150 180 210 240 270 300 0 20 40 60 80 100 PrevalenceofNewCasesby2022 (Thousands) New Therapies by 2023 1 clinicaltrials.gov 2 Each successful phase II and III trial that leads to an approval is defined as a new therapy 3 Historical FDA approval data is used for estimation 4Drugs that have already been approved and expected to receive approvals in other indications 20% Novel treatments (60)3 80% New indications (launched before)4 25%+ Combination therapies 7
  8. 8. 8 …MAKINGPATIENTEXPERIENCEINCREASINGLY IMPORTANT Copyright © 2018 Accenture. All rights reserved. Q5a. How much input do you currently have over the decision as to which new healthcare products and treatment options to select for your condition, from the full range of product and treatment options available in the market, that are different to what you use today? Q5b. How much input do you want to have over the decision as to which new healthcare products and treatment options to select for your condition, from the full range of product and treatment options available in the market, that are different to what you use today? Total (9234) Current input over new healthcare treatment decisions Desired input over new healthcare treatment decisions 44% 63%
  9. 9. Pinpoint 22biomarkers Driven by 14distinct technologies Address 15indications DECISIONMAKINGISINCREASINGLYCOMPLEX Copyright © 2019 Accenture All rights reserved. Sources: 1 Transparency Market research, 2 https://www.fda.gov/, 36FDA approved companion diagnostics2 Manufactured by 16 different companies as of 2018 USE CASE FOR NON-SMALL-CELL LUNG CANCER (NSCLC) Current: A patient is typically tested for multiple biomarkers simultaneously (ALK, EGFR, ROS, PD-L1). A targeted therapy is the first choice if patient is eligible. If not, PD-L1 status is considered for I-O therapy.2 Future: Comprehensive genome profiling + combination therapy options will make decision making even more complex. 9 BIOMARKERS ALLOW FOR THE SEGMENTATION OF TUMOR MARKETS AND LEADING TO A FAST GROWING COMPANION DIAGNOSTICS MARKET. BY 2025, ONCOLOGY WILL BE 87% OF A $13.6B COMPANION DIAGNOSTICS MARKET1 ALK = anaplastic lymphoma kinase EGFR = epidermal growth factor receptor ROS = Proto-oncogene tyrosine-protein kinase PD-L1 = Programmed death-ligand 1
  10. 10. 10 …CLINICALPATHWAYSAREBEINGINCREASINGLY IMPORTANTFORDECISIONMAKING Copyright © 2019 Accenture All rights reserved. CLINICAL PATHWAYS ARE BEING INCREASINGLY USED TO AID DECISION MAKING 60% of practice physicians regularly use clinical pathways in patient care1 38% of practices report using practice generated sources, as opposed to • P4 (10%) • payer generated (7.5%) • hospital generated(7.5%) • UPMC (6.25%), • Innovent/US Oncology (5%)2 54% of practices routinely measure physician compliance with clinical pathways3 42% increase in the number of oncology practices reporting compliance with a pathways program from 2014 to 20164 Sources:1,2,3 Transparency ASCO National Oncology Practice Benchmark;4 http://pharmaceuticalcommerce.com
  11. 11. 11 DECISIONMAKINGISINCREASINGLYCOMPLEX Copyright © 2019 Accenture All rights reserved. PAYERS ARE USING HEALTH-BASED OUTCOMES TO DETERMINE REIMBURSEMENT INNOVATION AGILITY IS A CONCERN Only 21% of payers are capable of rolling out a new episode of care program in less than 6 months1 PAYERS LACK CAPABILITY TO QUANTIFY VALUE More than 50% of payers are not satisfied with their current value-based analytics, automation, and reporting capabilities2 HEALTH-BASED OUTCOMES Conditional reimbursement rules and Performance Based Risk Sharing Arrangements are emerging, where performance is tracked in a defined patient population over a pre-specified period of time, and amount or level of reimbursement is based on outcomes achieved. USE CASE AstraZeneca and UK government agreed on deal where UK pays for Lynparza for the first 15 months of treatment, then AZ is responsible for the additional costs3 Sources: 1, 2 https://www.journalofclinicalpathways.com 3 https://www.telegraph.co.uk/finance/newsbysector/pharmaceuticalsandchemicals/12045335/AstraZeneca-cancer-drug-approved-on-NHS-but-with-strings-attached.html
  12. 12. ACTIONSTOLAUNCH NEWTREATMENTS ANDACHIEVEGROWTH INONCOLOGY Copyright © 2019 Accenture All rights reserved. 12 ▌ Simplify decision making for Oncologists and patients. ▌ Consider the entire patient experience starting with clinical trial design. ▌ Bring a steady stream of evidence that your treatment delivers a better outcome in a real- world setting.
  13. 13. SIMPLIFYDECISIONMAKING FORONCOLOGISTSAND PATIENTS Copyright © 2019 Accenture All rights reserved. Ensure trial results are easy to interpret in a real-world setting. Connect results to the patient populations and simplify messaging so the choice is clear to oncologist and the patient. Move from informative decision tools to aids for actual decision making in the clinic. Raise awareness using oncology conferences (ASCO, ESMO, and others). Make it easy to work with other physicians (peers) 13
  14. 14. CONSIDERTHEENTIRE PATIENTEXPERIENCE STARTINGWITH CLINICALTRIALDESIGN Copyright © 2019 Accenture All rights reserved. ▌Reduce dosing schedule requiring less hospital visits by elongating the time between doses (e.g. every four weeks vs. every six weeks make a difference). ▌Different treatment administration methods to completely eliminate travel to infusion centers – Oral or sub-cutaneous. 14
  15. 15. BRINGASTEADYSTREAMOF EVIDENCE THATYOURTREATMENTDELIVERSABETTER OUTCOMEINAREAL-WORLDSETTING Copyright © 2019 Accenture All rights reserved. ▌ Invest time and money to continuously create real-world evidence (RWE) for clinical outcomes as payers increase use of health-based outcomes to determine reimbursement. ▌ Be creative with your pricing method – use the full toolkit (outcome based, indication-based pricing, etc.) ▌ Use outcomes to secure treatment coverage. Many patients cannot afford cancer treatments costing greater than $100,000/year. 15
  16. 16. 16 FORMOREINFORMATIONPLEASEVISIT OURPRECISIONONCOLOGYWEBSITE Copyright © 2019 Accenture All rights reserved. Selen Karaca-Griffin Business Strategy Senior Manager, Accenture Strategy https://www.linkedin.com/in/selen-karaca-griffin- 95a64625/ Dr. Boris Bogdan Managing Director, Lead – Global Precision Oncology and PHC, Accenture Life Sciences https://www.linkedin.com/in/borisbogdan/ CONTACT US STAY CONNECTED linkedin.com/company/accenture_life_sciences @AccentureLifeSci www.accenture.com/lifesciencesblog

×